Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2010-8-17
pubmed:abstractText
Lentiviral-mediated beta-globin gene transfer successfully treated beta-thalassemic mice. Based on this result, clinical trials were initiated. To date, however, no study has investigated the efficacy of gene therapy in relation to the nature of the different beta-globin mutations found in patients. Most mutations can be classified as beta(0) or beta(+), based on the amount of beta-globin protein produced. Therefore, we propose that a screening in vitro is necessary to verify the efficacy of gene transfer prior to treatment of individual patients. We used a two-phase liquid culture system to expand and differentiate erythroid progenitor cells (ErPCs) transduced with lentiviral vectors. We propose the use of this system to test the efficiency of lentiviral vectors carrying the human beta-globin gene, to correct the phenotype of ErPCs from patients preparing for gene therapy. This new approach might have profound implications for designing gene therapy and for understanding the genotype/phenotype variability observed in Cooley's anemia patients.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-10074136, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-10775605, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-10894546, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-11023527, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-11877258, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-12435053, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-12480689, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-1583734, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-16339679, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-20007873, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-2016766, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-2072454, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-6101206, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-6264477, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-7568113, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-8318917, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-8524813, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-9733856, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-9765382, http://linkedlifedata.com/resource/pubmed/commentcorrection/20712784-9811723
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1749-6632
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
1202
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
134-40
pubmed:dateRevised
2011-8-3
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
A preclinical approach for gene therapy of beta-thalassemia.
pubmed:affiliation
Department of Pediatrics, Division of Hematology-Oncology, Weill Cornell Medical College, Children's Blood and Cancer Foundation Laboratories, New York, New York, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural